{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-238237","form_type":"8-K","ticker":"TCRT","cik":"0001107421","company_name":"Alaunos Therapeutics, Inc.","filed_at":"2026-05-26T15:00:21+00:00","discovered_at":"2026-05-26T15:02:00.299303+00:00","generated_at":"2026-05-26T15:02:37.902818+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"confidence":"high","headline":"Alaunos reports ALN1003 preclinical data: -12.9% weight loss, liver weight -43%; cash only $0.35M","bullets":["ALN1003 in DIO mice: mean body weight change -12.9% by Day 33 and -10.3% by Day 48 (p<0.0001).","Liver weight reduced 43% (p<0.0001); lower ALT, AST, ALP and improved histology in treated animals.","Favorable body composition shift: fat -44.6% (grams), lean +17.2% as % body weight (high dose).","Cash and cash equivalents $0.354M as of March 31, 2026; runway into Q2 2026, needs additional financing.","Data from non-GLP mouse studies only; ALN1003 has not been tested in humans."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-238237","json":"https://secwatch.observer/filing/0001193125-26-238237.json","markdown":"https://secwatch.observer/filing/0001193125-26-238237.md","text":"https://secwatch.observer/filing/0001193125-26-238237.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1107421/000119312526238237/0001193125-26-238237-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1107421/000119312526238237/tcrt-20260526.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T15:02:37.902818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}